The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection

por Shalev, Itay, Selzner, Nazia, Helmy, Ahmed, Foerster, Katharina, Adeyi, Oyedele A., Grant, David R., Levy, Gary
Publicado 2010

Murine Hepatitis Virus Strain 1 as a Model for Severe Acute Respiratory Distress Syndrome (Sars)

por DeAlbuquerque, Nadine, Baig, Ehtesham, Xuezhong, Max, Shalev, Itay, Phillips, M. James, Habal, Marlena, Leibowitz, Julian, McGilvray, Ian, Butany, Jagdish, Fish, Eleanor, Levy, Gary
Publicado 2006

Targeted Deletion of FGL2 Leads to Increased Early Viral Replication and Enhanced Adaptive Immunity in a Murine Model of Acute Viral Hepatitis Caused by LCMV WE

por Khattar, Ramzi, Luft, Olga, Yavorska, Nataliya, Shalev, Itay, Phillips, M. James, Adeyi, Oyedele, Gao, Darrin, Bartczak, Agata, Urbanellis, Peter, Shyu, Wendy, Zhang, Jianhua, Manuel, Justin, Levy, Gary A., Selzner, Nazia
Publicado 2013

Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4(+) CD25(+) Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice

por Wang, Junhua, Vuitton, Dominique A., Müller, Norbert, Hemphill, Andrew, Spiliotis, Markus, Blagosklonov, Oleg, Grandgirard, Denis, Leib, Stephen L., Shalev, Itay, Levy, Gary, Lu, Xiaomei, Lin, Renyong, Wen, Hao, Gottstein, Bruno
Publicado 2015